Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 6, 2011, Pages 3334-3337

  Wolf Schnurrbusch, Ute E K ^a,b   Ghanem, Ramzi ^a,c   Rothenbuehler, Simon P ^b   Enzmann, Volker ^a   Framme, Carsten ^a   Wolf, Sebastian ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Helios Klinikum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; EXTERNAL LIMITING MEMBRANE; EYE PHOTOGRAPHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; OPHTHALMOSCOPY; PHOTORECEPTOR INNER SEGMENT; PHOTORECEPTOR OUTER SEGMEN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA; RETINA MACULA EDEMA; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT OUTCOME; VISUAL ACUITY; CLINICAL TRIAL; DRUG ANTAGONISM; EPIRETINAL MEMBRANE; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHOTORECEPTOR CELL; PHYSIOLOGY; RETINA VEIN OCCLUSION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; EPIRETINAL MEMBRANE; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; OPHTHALMOSCOPY; PHOTORECEPTOR CELLS, VERTEBRATE; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; YOUNG ADULT;

EID: 80051556255     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6097     Document Type: Article

References (21)

1. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010; 117(2):313-319.
2. David R, Zangwill L, Badarna M, Yassur Y. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica. 1988;197(2):69-74.
3. Rath EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein occlusions: a case-control study. Ophthalmology. 1992;99:509-514.
4. Argon laser photocoagulation for macular edema in branch vein occlusion: the Branch Vein Occlusion Study Group. Am J Ophthalmol. 1984;98(3):271-282.
5. Central vein occlusion study of photocoagulation therapy: Baseline findings: The Central Vein Occlusion Study Group. Online J Curr Clin Trials. 1993;Doc No 95.
6. Klein ML, Finkelstein D. Macular grid photocoagulation for macular edema in central retinal vein occlusion. Arch Ophthalmol. 1989;107:1297-1302.
7. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion. Eur J Ophthalmol. 2005;15:751-758.
8. Berker N, Batman C. Surgical treatment of central retinal vein occlusion. Acta Ophthalmol. 2008;86:245-252.
9. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina. 2007;27:141-149.
10. Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina. 2007;27:1004-1012.
11. Jaissle GB, Ziemssen F, Petermeier K, et al. [Bevacizumab for treatment of macular edema secondary to retinal vein occlusion]. Ophthalmologe. 2006;103:471-475.
12. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006;26:279-284.
13. Ach T, Hoeh AE, Schaal KB, Scheuerle AF, Dithmar S. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2010;248;155-159.
14. Natural history and clinical management of central retinal vein occlusion: the Central Vein Occlusion Study Group. Arch Ophthalmol. 1997;115:486-491.
15. Chen JC, Klein ML, Watzke RC, Handelman IL, Robertson JE. Natural course of perfused central retinal vein occlusion. Can J Ophthalmol. 1995;30:21-24.
16. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008;126:513-518.
17. Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005;140:256-261.
18. Noma H, Funatsu H, Mimura T, Hori S. Changes of vascular endothelial growth factor after vitrectomy for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol. 2008;18:1017-1019.
19. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology. 1998;105:412-416.
20. Matsumoto Y, Freund KB, Peiretti E, Cooney MJ, Ferrara DC, Yannuzzi LA. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina. 2007;27:426-431.
21. Lang GE, Handel A. Clinical and fluorescein angiography changes in patients with central retinal vein occlusion: a unicenter study of 125 patients. Klin Monbl Augenheilkd. 1992;201:302-308.